With the recent interest in full disclosure of information about clinical trials, national bodies and regulators should not tolerate keeping information confidential that may impede good decision making. Academic or commercial pressure to limit access to data is denying clinicians valuable information. An example of this relates to the antifibrotic drug ▼pirfenidone, which received marketing authorisation in 2011 for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF).1 Pirfenidone has been shown to slow the decline in forced vital capacity (FVC) compared with placebo,2 and has been approved for use by the National Institute for Health and Care …